Compare PAYS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYS | CABA |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.4M | 319.6M |
| IPO Year | 2020 | 2019 |
| Metric | PAYS | CABA |
|---|---|---|
| Price | $6.04 | $3.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $9.42 | ★ $14.50 |
| AVG Volume (30 Days) | 788.5K | ★ 4.3M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.71 | 10.26 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $24,120,434.00 | N/A |
| Revenue This Year | $33.83 | N/A |
| Revenue Next Year | $14.89 | N/A |
| P/E Ratio | $65.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $1.26 |
| 52 Week High | $8.88 | $4.23 |
| Indicator | PAYS | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 49.77 | 46.13 |
| Support Level | $5.09 | $2.17 |
| Resistance Level | $7.05 | $3.54 |
| Average True Range (ATR) | 0.48 | 0.34 |
| MACD | -0.15 | -0.05 |
| Stochastic Oscillator | 55.26 | 33.33 |
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.